Author's response to reviews

Title: c-Met in esophageal squamous cell carcinoma: Independent prognostic factor and potential therapeutic target

Authors:

Yohei Ozawa (ozawa.youhei@opal.plala.or.jp)
Yasuhiro Nakamura (yasu-naka@patholo2.med.tohoku.ac.jp)
Fumiyoshi Fujishima (ffujishima@patholo2.med.tohoku.ac.jp)
Saulo J.A Felizola (felizola@med.tohoku.ac.jp)
Kenichiro Takeda (takeda.kenichirou@me.com)
Hiroshi Okamoto (qq4b2ev9k@beach.ocn.ne.jp)
Ken Ito (fafafapdx2000@yahoo.co.jp)
Hirotaka Ishida (hirotaka_1106@yahoo.co.jp)
Takuro Konno (supo4bowling9@yahoo.co.jp)
Takashi Kamei (tkamei@med.tohoku.ac.jp)
Go Miyata (miyata5@chuo-hp.jp)
Noriaki Ohuchi (noriaki-ohuchi@med.tohoku.ac.jp)
Hironobu Sasano (hsasano@patholo2.med.tohoku.ac.jp)

Version: 2
Date: 16 October 2014

Author's response to reviews: see over
Oct 15, 2014

Dafne Solera
Editor-in-Chief
BMC cancer

Dear Dr. Solera:

I, along with my coauthors, would like to ask you to consider the attached manuscript entitled “c-Met in esophageal squamous cell carcinoma: Independent prognostic factor and potential therapeutic target” for publication in BMC cancer as a research article.

Esophageal squamous cell carcinoma (ESCC) is known to have highly malignant characteristics. A combination of surgical and chemo/chemoradiotherapy is the main treatment for ESCC patients, as molecular targeted therapy has not been fully developed. The present study focused on c-Met, a transmembrane receptor tyrosine kinase, widely known as a poor prognostic factor in various carcinomas but undefined in ESCC. Our results identified c-Met expression as an independent prognostic factor in ESCC patients and demonstrated that c-Met might be a molecular therapeutic target for ESCC.

We believe that the findings of this study are relevant to the scope of your journal and will be of interest to its readership.

This manuscript has not been published elsewhere in part or in entirety, and is not under consideration by another journal. All study participants provided informed consent, and the study design was approved by the appropriate ethics review boards. All the authors have approved the manuscript and agree with submission to your esteemed journal. There are no conflicts of interest to declare.

Thank you for your consideration. I look forward to hearing from you.

Sincerely,
Yohei Ozawa
Division of Advanced Surgical Science and Technology, Tohoku University Graduate School of Medicine
1-1 Seiryo-machi, Aoba-ku, Sendai 980-8574, Japan
Email address: ozawa.youhei@opal.plala.or.jp
Phone: +81-22-717-7214
Fax: +81-22-717-7217